Sensei Biotherapeutics, Inc. ( (SNSE) ) has released its Q4 earnings. Here is a breakdown of the information Sensei Biotherapeutics, Inc. presented to its investors.
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of next-generation cancer therapeutics, with a focus on conditionally active biologics targeting the tumor microenvironment.
In its latest earnings report, Sensei Biotherapeutics highlighted significant progress in its clinical trials, particularly with its lead product candidate, solnerstotug, which has shown promising results in treating PD-(L)1 resistant tumors. The company also reported financial results for the full year 2024, noting a decrease in net loss compared to the previous year.
Key financial metrics from the report include a net loss of $30.2 million for 2024, an improvement from the $34.1 million loss in 2023. Research and development expenses slightly increased to $18.6 million, while general and administrative expenses decreased significantly to $13.0 million. The company maintains a cash runway into the second quarter of 2026, with cash and marketable securities totaling $41.3 million as of December 31, 2024.
Strategically, Sensei has achieved target enrollment in its Phase 1/2 trial for solnerstotug and anticipates full data by the end of 2025. The trial results so far indicate a 14% overall response rate and a 62% disease control rate in PD-(L)1 resistant tumors, with a favorable safety profile.
Looking ahead, Sensei Biotherapeutics is focused on advancing solnerstotug through its clinical trials and refining its Phase 2 strategy, with the aim of providing new treatment options for cancer patients resistant to existing therapies.